WO2011034039A1 - Eradicating agent and eradication method for helicobacter pylori - Google Patents
Eradicating agent and eradication method for helicobacter pylori Download PDFInfo
- Publication number
- WO2011034039A1 WO2011034039A1 PCT/JP2010/065787 JP2010065787W WO2011034039A1 WO 2011034039 A1 WO2011034039 A1 WO 2011034039A1 JP 2010065787 W JP2010065787 W JP 2010065787W WO 2011034039 A1 WO2011034039 A1 WO 2011034039A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pylori
- ammonia
- helicobacter pylori
- activated carbon
- stomach
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a disinfectant for Helicobacter pylori (hereinafter referred to as “H. pylori” as appropriate) and a disinfecting method using the disinfectant.
- Helicobacter pylori is a chronic or recurrent factor of chronic gastritis, stomach and duodenal ulcer, and it is said that 50% of the world population is infected. This H. pylori can grow only in the stomach of animals in the natural environment and has been shown to infect humans, monkeys, cats, pigs and dogs. Helicobacter pylori has urease activity and is considered to live in a strong acidic environment in the stomach by neutralizing gastric acid by producing ammonia from urea.
- Non-Patent Document 1 Three-drug combination therapy combining antibiotics (amoxicillin, clarithromycin) and proton pump inhibitors is being used to eliminate H. pylori. Due to the emergence of antibiotic-resistant bacteria, It is becoming difficult to completely sterilize by the method (Non-Patent Document 1). For this reason, secondary and tertiary sterilization methods using new antibiotics (metronidazole, levofloxane) have also been attempted. However, since these sterilization methods also affect the function of enteric bacteria useful for the human body, there is a problem that side effects such as diarrhea are involved.
- Patent Document 1 a brown reaction product administration agent of sugar and protein
- Patent Document 2 A method of administering fucoidan that inhibits
- Patent Document 3 a method of administering saccharides having ⁇ 1-4 bonds that suppress the growth of H. pylori
- Patent Document 3 a method of administering saccharides having ⁇ 1-4 bonds that suppress the growth of H. pylori
- Non-patent Document 2 combined treatment with probiotics (lactic acid bacteria etc.) has also been reported.
- Non-patent Document 2 it is difficult to say that these mechanisms of action have been clarified and have not yet been established as a sterilization method.
- JP 2008-024662 A Japanese Patent Laid-Open No. 07-138166 JP 2008-120789 A
- an object of the present invention is to provide a novel disinfectant for Helicobacter pylori and a disinfecting method using the same.
- the present inventors have conducted earnest research focusing on the fact that Helicobacter pylori can live in a strongly acidic environment in the stomach because it produces ammonia from urea and neutralizes gastric acid. As a result, it was found that by introducing an adsorbent of ammonia or ammonium ions into the stomach and making it difficult for H. pylori to live, it was found that H. pylori can be sterilized and the present invention was completed. . Specifically, the present invention is as follows.
- a Helicobacter pylori disinfectant containing an ammonia or ammonium ion adsorbent (2) The disinfectant according to (1), wherein the ammonia or ammonium ion adsorbent is at least one selected from the group consisting of activated carbon, silica gel, alumina, zeolite, and a cation exchange material. (3) A method for sterilizing Helicobacter pylori, wherein the sterilizing agent according to (1) or (2) is introduced into a stomach infected with Helicobacter pylori.
- FIG. 2C is a diagram showing a colony area (mm 2 ) in FIGS. 2A to 2C.
- FIG. H. pylori was mixed with PBS and inoculated into an agar medium.
- FIG. 5 is a diagram showing the width (mm) of the growth inhibition zone in (1) to (3) of FIG. 4 and the ammonia adsorption capacity (ppm) of the activated carbon powder used in (1) to (3).
- the Helicobacter pylori disinfectant according to the present invention contains an adsorbent of ammonia or ammonium ions. Moreover, the sterilization method of Helicobacter pylori according to the present invention introduces the disinfectant according to the present invention into the stomach infected with Helicobacter pylori.
- H. pylori can live in a strongly acidic environment in the stomach because it produces ammonia from urea and neutralizes gastric acid. Therefore, in the method for sterilizing Helicobacter pylori according to the present invention, a sterilizing agent containing an adsorbent for ammonia or ammonium ions is introduced into the stomach, and the ammonia or ammonium ions are adsorbed, so that Helicobacter pylori is less likely to live. And sterilize H. pylori. In other words, the sterilization method according to the present invention sterilizes H. pylori by interfering with neutralization of gastric acid. This is an indirect sterilization method as opposed to a direct sterilization method with antibiotics.
- H. pylori is only present on the gastric mucosal surface and has not been found in the deep gastric mucosa. The reason is that cis-N-acetyl-D-glucosamine at the end of the sugar chain of a specific glycoprotein present in the deep gastric mucosa suppresses the growth of Helicobacter pylori (Science, vol. 305, 2004). , Pp. 1003-1006). Thus, since H. pylori is resident on the gastric mucosal surface, it is considered that the disinfectant reaches the periphery of H. pylori only by introducing it into the stomach.
- the adsorbent for ammonia or ammonium ions is not particularly limited as long as it has an adsorption ability for ammonia or ammonium ions.
- at least one selected from the group consisting of activated carbon, silica gel, alumina, zeolite, and cation exchange material can be used.
- These adsorbents are preferably in the form of powder or fine particles from the viewpoint of enhancing the adhesion to the gastric mucosa and the ability to adsorb ammonia or ammonium ions.
- the carbon raw material used as the raw material for the activated carbon known raw materials such as sawdust, wood, palm grain, oil carbon, phenol resin, cellulose, acrylonitrile, coal pitch, and petroleum pitch can be used.
- high-purity cellulose having a purity of 90% or more is preferable, and high-purity cellulose having a purity of 95% or more is more preferable.
- Known materials such as copper ammonia rayon, viscose rayon, cotton, pulp, linter, polynosic, and lyocell (Tencel) can be used as the high purity cellulose material.
- the above carbon raw material is fired in an electric furnace or the like.
- the firing temperature is preferably 300 to 1500 ° C, more preferably 500 to 1000 ° C.
- the calcination temperature is lower to adsorb ammonia.
- this activated carbon may be activated or not activated.
- silica gel, alumina, and zeolite those conventionally used as adsorbents for ammonia or ammonium ions can be used without particular limitation.
- a strong acid cation exchange resin having —SO 3 H as a functional group
- a weak acid cation exchange resin having —COOH as a functional group
- adsorbents may be coated with a hydrophilic porous polymer such as cellulose, nitrocellulose, gelatin, polyacrylamide, or polymethacrylate. By covering in this way, damage to gastric mucosal cells can be prevented.
- a hydrophilic porous polymer such as cellulose, nitrocellulose, gelatin, polyacrylamide, or polymethacrylate.
- Examples of the method for introducing the disinfectant according to the present invention into the stomach include oral administration and direct administration while observing with an endoscope.
- oral administration processing into powders, granules, tablets, dragees, capsules, liquids and the like may be performed as necessary.
- it can be mixed with foods (gum, candy, jelly, yogurt, etc.) and beverages and ingested in the same manner as ordinary foods and drinks.
- the disinfectant according to the present invention is not digested or absorbed in the stomach and does not damage the gastric mucosa. Therefore, H. pylori can be gradually reduced by introducing an appropriate amount into the stomach continuously for a certain period without worrying about side effects. In particular, if a material used for food or medical use is used, a safe and inexpensive disinfectant can be provided. Furthermore, from the mechanism of the disinfectant according to the present invention, a disinfecting effect can be expected for antibiotic-resistant (insensitive) bacteria.
- the sterilization method according to the present invention may be performed alone, it may be used in combination with a conventionally known sterilization method.
- the effect of reducing the amount of antibiotics to be used can be expected by sterilization by the triple-drug combination therapy after sterilization by the sterilization method according to the present invention (Hericobacter Research, vol. 8, No. 1, 24, pp. 86-87).
- Example 1 In order to evaluate the sterilization effect of Helicobacter pylori, the following experiment was conducted.
- the Helicobacter pylori used in this experiment is a strain (Campylobacter pylori subsp. Pylori, JCM No. 12093) provided by RIKEN BioResource Center.
- As the culture dish the following two types (a) and (b) were used.
- B H. pylori agar medium (manufactured by Kyokuto Pharmaceutical Co., Ltd., code05561)
- the culture dish (a) was used for growth to stock H. pylori strains.
- the culture dish of (b) is for observing the state of bacterial cells (colony formation) after each treatment described below on H. pylori grown in the culture dish of (a). used.
- This H. pylori agar medium is characterized by the fact that growth other than H. pylori is suppressed by the selection agent added to the medium, and that the colony of H. pylori is colored purple by the addition of tetrazolium biored. There is.
- pylori is mixed with 0.7 mL of PBS, inoculated on H. pylori agar medium, and set for anero-pack microaerobic pouch (microaerobic culture, oxygen concentration 6-12%, carbon dioxide concentration 5-8% Cultivated at 37 ° C. for 3 days using Mitsubishi Gas Chemical Co., Ltd., MGC A-18).
- microaerobic culture oxygen concentration 6-12%, carbon dioxide concentration 5-8% Cultivated at 37 ° C. for 3 days using Mitsubishi Gas Chemical Co., Ltd., MGC A-18.
- the appearance of colony formation after culture is shown in FIG.
- H. pylori was mixed with 0.7 mL of PBS, inoculated on each of the three H. pylori agar media, and cultured at 37 ° C. for 1 day using the above set for aneropack microaerobic pouch. Then, 0.5 mL of 0.1M hydrochloric acid is sprayed on one H. pylori agar medium, and activated charcoal powder A or activated carbon powder B (both 10 mg) that has not been activated is dispersed in the remaining two H. pylori agar mediums. After spraying 0.5 mL of 0.1 M hydrochloric acid, the cells were further cultured for 3 days.
- the activated carbon powder A is fired at 1000 ° C. and has a low ammonia adsorption capacity
- the activated carbon powder B is fired at 500 ° C. and has a high ammonia adsorption capacity.
- FIGS. 2A to 2C The appearance of colony formation after culture is shown in FIGS. 2A to 2C.
- 2A shows the case where the activated carbon powder is not dispersed
- FIG. 2B shows the case where the activated carbon powder A is dispersed
- FIG. 2C shows the case where the activated carbon powder B is dispersed.
- the colony is circled.
- the sum total of the colony area (mm ⁇ 2 >) in each is shown in FIG.
- H. pylori grew when sprayed with PBS or 0.1M hydrochloric acid, but when 0.1M hydrochloric acid dispersed with activated carbon powders A and B was sprayed, Number and area decreased. Moreover, this reduction rate was positively correlated with the ammonia adsorption capacity.
- This result suggests the following. In other words, in order for H. pylori to grow in hydrochloric acid, it is necessary to decompose urea with urease to generate ammonia and neutralize hydrochloric acid. However, ammonia is adsorbed in the presence of activated carbon, so hydrochloric acid Can not be neutralized, it will continue to be exposed to hydrochloric acid, and breeding will be inhibited.
- H. pylori was mixed with 0.7 mL of PBS, inoculated on one H. pylori agar medium, and cultured at 37 ° C. for 1 day using the above set for aneropack microaerobic pouch.
- a hole with a diameter of 7 mm is provided at the four corners of the H. pylori agar medium, and 0.2 mL of 0.1 M hydrochloric acid or 5 mL of 0.1 M hydrochloric acid in which 5 mg of a commercially available product or a prototype activated carbon powder is dispersed. Filled and further cultured for 3 days.
- FIG. (1) in FIG. 4 is a dispersion of activated carbon powder (prototype) obtained by firing high-purity cellulose at 500 ° C.
- (2) is an activated carbon powder (prototype) obtained by firing high-purity cellulose at 1000 ° C.
- (3) is obtained by dispersing “Kremezin” manufactured by Kureha Chemical Industry, and (4) is obtained by not dispersing activated carbon powder.
- FIG. 5 shows the width (mm) of the growth inhibition zone in (1) to (3) of FIG. 4 and the ammonia adsorption capacity (ppm) of the activated carbon powder used in (1) to (3).
- FIGS. 4 and 5 a colony growth inhibition zone was observed around the hole, and its width correlated positively with the ammonia adsorption capacity.
- a large growth inhibition zone is also observed in (4) of FIG. 4 because the amount of hydrochloric acid is large by an amount corresponding to the volume of 5 mg of the activated carbon powder and is continuously exposed to excess hydrochloric acid.
- H. pylori was mixed with 0.7 mL of PBS, inoculated on each of the three H. pylori agar media, and cultured at 37 ° C. for 1 day using the above set for aneropack microaerobic pouch.
- Each H. pylori agar medium was sprayed with 0.5 mL of 0.1M hydrochloric acid in which 10 mg of cellulose (Asahi Kasei, Theolas 101) or 10 mg of silica gel (Chemco, LC-SORB SPW-B-Si) was dispersed. Cultured for 3 days.
- FIGS. 6A and 6B The appearance of colony formation after culture is shown in FIGS. 6A and 6B.
- FIG. 6A shows a dispersion of cellulose
- FIG. 6B shows a dispersion of silica gel.
- the growth inhibitory effect was not confirmed with cellulose that does not have the ability to adsorb ammonia or ammonium ions, but the growth inhibitory effect was confirmed with silica gel. This is presumably because silica gel has a low ammonia adsorption ability, but can adsorb ammonium ions generated by the reaction of ammonia with hydrochloric acid by electrostatic interaction. Therefore, the same effect can be expected in the cation exchange material.
- Example 2 In order to examine the sterilization effect of activated carbon, a urea breath test (UBT) was conducted with the consent of two persons infected with H. pylori. First, a urea breath test was conducted on two test cooperators, and the amount of Helicobacter pylori in the stomach (UBT value: ⁇ 13 C ( ⁇ )) was calculated from the ratio of the concentration of carbon dioxide containing 13 C in the breath. Thereafter, two capsules of activated carbon powder (prototype) calcined at 1000 ° C. containing high-purity cellulose (including 180 mg of activated carbon powder per tablet) were orally ingested 3 times a day after meals, and expired after ingestion for 3 weeks.
- activated carbon powder prototype
- the amount of Helicobacter pylori in the stomach (UBT value: ⁇ 13 C ( ⁇ )) was calculated from the ratio of carbon dioxide gas concentration containing 13 C therein.
- a carbon dioxide isotope ratio analyzer manufactured by Otsuka Electronics Co., Ltd., POC one was used. Exhalation sampling and manipulation were performed according to the manufacturer's instructions. The results are shown in Table 1 below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(2) 前記アンモニア又はアンモニウムイオンの吸着材が、活性炭、シリカゲル、アルミナ、ゼオライト、及び陽イオン交換材からなる群から選択される少なくとも1種である上記(1)記載の除菌剤。
(3) ヘリコバクター・ピロリに感染した胃内に上記(1)又は(2)記載の除菌剤を導入するヘリコバクター・ピロリの除菌方法。 (1) A Helicobacter pylori disinfectant containing an ammonia or ammonium ion adsorbent.
(2) The disinfectant according to (1), wherein the ammonia or ammonium ion adsorbent is at least one selected from the group consisting of activated carbon, silica gel, alumina, zeolite, and a cation exchange material.
(3) A method for sterilizing Helicobacter pylori, wherein the sterilizing agent according to (1) or (2) is introduced into a stomach infected with Helicobacter pylori.
上記陽イオン交換材としては、強酸性陽イオン交換樹脂(官能基として-SO3Hを有する)、弱酸性陽イオン交換樹脂(官能基として-COOHを有する)等を用いることができる。 As the silica gel, alumina, and zeolite, those conventionally used as adsorbents for ammonia or ammonium ions can be used without particular limitation.
As the cation exchange material, a strong acid cation exchange resin (having —SO 3 H as a functional group), a weak acid cation exchange resin (having —COOH as a functional group), or the like can be used.
特に、経口投与する場合には、必要に応じて、散剤、顆粒剤、錠剤、糖衣錠、カプセル剤、液剤等への加工を行ってもよい。また、食品(ガム、キャンディー、ゼリー、ヨーグルト等)や飲料に混入させ、通常の飲食品と同様に摂取することも可能である。 Examples of the method for introducing the disinfectant according to the present invention into the stomach include oral administration and direct administration while observing with an endoscope.
In particular, in the case of oral administration, processing into powders, granules, tablets, dragees, capsules, liquids and the like may be performed as necessary. Moreover, it can be mixed with foods (gum, candy, jelly, yogurt, etc.) and beverages and ingested in the same manner as ordinary foods and drinks.
さらに、本発明に係る除菌剤のメカニズムから、抗生物質耐性(非感受性)菌に対しても除菌効果が期待できる。 The disinfectant according to the present invention is not digested or absorbed in the stomach and does not damage the gastric mucosa. Therefore, H. pylori can be gradually reduced by introducing an appropriate amount into the stomach continuously for a certain period without worrying about side effects. In particular, if a material used for food or medical use is used, a safe and inexpensive disinfectant can be provided.
Furthermore, from the mechanism of the disinfectant according to the present invention, a disinfecting effect can be expected for antibiotic-resistant (insensitive) bacteria.
ピロリ菌の除菌効果を評価するために、以下の実験を行った。
本実験で使用したピロリ菌は、理化学研究所バイオリソースセンターより提供された菌株(Campylobacter pylori subsp. pylori、JCM No.12093)である。
培養ディッシュとしては以下(a),(b)の2種類を用いた。
(a)トリプチケースソイII 5%ヒツジ血液寒天培地(Becton Dickinson製、cat251239)
(b)ピロリ寒天培地(極東製薬製、code05561)
上記(a)の培養ディッシュは、ピロリ菌株をストックするための増殖に使用した。
また、上記(b)の培養ディッシュは、上記(a)の培養ディッシュで増殖されたピロリ菌に対し、以下に述べる各々の処理をした後で菌体(コロニー形成)の様子を観察するために使用した。このピロリ寒天培地は、培地に添加されている選択剤により、ピロリ菌以外の発育が抑制され、また、テトラゾリウムバイオレッドの添加によりピロリ菌のコロニーが紫色に着色するため確認が容易であるといった特徴がある。 [Example 1]
In order to evaluate the sterilization effect of Helicobacter pylori, the following experiment was conducted.
The Helicobacter pylori used in this experiment is a strain (Campylobacter pylori subsp. Pylori, JCM No. 12093) provided by RIKEN BioResource Center.
As the culture dish, the following two types (a) and (b) were used.
(A)
(B) H. pylori agar medium (manufactured by Kyokuto Pharmaceutical Co., Ltd., code05561)
The culture dish (a) was used for growth to stock H. pylori strains.
The culture dish of (b) is for observing the state of bacterial cells (colony formation) after each treatment described below on H. pylori grown in the culture dish of (a). used. This H. pylori agar medium is characterized by the fact that growth other than H. pylori is suppressed by the selection agent added to the medium, and that the colony of H. pylori is colored purple by the addition of tetrazolium biored. There is.
なお、活性炭粉末Aは1000℃で焼成したものであり、アンモニア吸着能が低く、活性炭粉末Bは500℃で焼成したものであり、アンモニア吸着能が高い。 Next, H. pylori was mixed with 0.7 mL of PBS, inoculated on each of the three H. pylori agar media, and cultured at 37 ° C. for 1 day using the above set for aneropack microaerobic pouch. Then, 0.5 mL of 0.1M hydrochloric acid is sprayed on one H. pylori agar medium, and activated charcoal powder A or activated carbon powder B (both 10 mg) that has not been activated is dispersed in the remaining two H. pylori agar mediums. After spraying 0.5 mL of 0.1 M hydrochloric acid, the cells were further cultured for 3 days.
The activated carbon powder A is fired at 1000 ° C. and has a low ammonia adsorption capacity, and the activated carbon powder B is fired at 500 ° C. and has a high ammonia adsorption capacity.
ピロリ菌を0.7mLのPBSで混釈し、1つのピロリ寒天培地に植菌後、上記のアネロパック微好気パウチ用セットを使用して、37℃で1日間培養した。そして、ピロリ寒天培地の4隅に直径7mmの穴を設け、その中に、市販品又は試作品の活性炭粉末5mgを分散させた0.1M塩酸0.2mL、又は0.1M塩酸0.2mLを満たし、さらに3日間培養した。 Next, in order to make the culture conditions the same, the same experiment was performed using only one H. pylori agar medium.
H. pylori was mixed with 0.7 mL of PBS, inoculated on one H. pylori agar medium, and cultured at 37 ° C. for 1 day using the above set for aneropack microaerobic pouch. A hole with a diameter of 7 mm is provided at the four corners of the H. pylori agar medium, and 0.2 mL of 0.1 M hydrochloric acid or 5 mL of 0.1 M hydrochloric acid in which 5 mg of a commercially available product or a prototype activated carbon powder is dispersed. Filled and further cultured for 3 days.
ピロリ菌を0.7mLのPBSで混釈し、3つのピロリ寒天培地にそれぞれ植菌後、上記のアネロパック微好気パウチ用セットを使用して、37℃で1日間培養した。そして、各ピロリ寒天培地にセルロース(旭化成製、セオラス101)10mg、又はシリカゲル(ケムコ製、LC-SORB SPW-B-Si)10mgを分散させた0.1M塩酸0.5mLを散布して、さらに3日間培養した。 Next, the same experiment was performed using silica gel as an adsorbent other than activated carbon. Cellulose was used as a control.
H. pylori was mixed with 0.7 mL of PBS, inoculated on each of the three H. pylori agar media, and cultured at 37 ° C. for 1 day using the above set for aneropack microaerobic pouch. Each H. pylori agar medium was sprayed with 0.5 mL of 0.1M hydrochloric acid in which 10 mg of cellulose (Asahi Kasei, Theolas 101) or 10 mg of silica gel (Chemco, LC-SORB SPW-B-Si) was dispersed. Cultured for 3 days.
活性炭による除菌効果を調べるため、ピロリ菌の感染者2名の同意のもとで尿素呼気試験(UBT)を行った。
まず、試験協力者2名について尿素呼気試験を行い、呼気中の13Cを含む炭酸ガス濃度の比率から、胃中のピロリ菌量(UBT値:Δ13C(‰))を算出した。その後、高純度セルロースを1000℃で焼成した活性炭粉末(試作品)のカプセル2錠(1錠あたり180mgの活性炭粉末を含む)を1日3回、食後に経口摂取させ、3週間摂取後における呼気中の13Cを含む炭酸ガス濃度の比率から、胃中のピロリ菌量(UBT値:Δ13C(‰))を算出した。呼気試験装置としては、炭酸ガス同位体比分析装置(大塚電子製、POC one)を用いた。呼気のサンプリング及び操作はメーカの取扱説明書に従って行った。結果を下記表1に示す。 [Example 2]
In order to examine the sterilization effect of activated carbon, a urea breath test (UBT) was conducted with the consent of two persons infected with H. pylori.
First, a urea breath test was conducted on two test cooperators, and the amount of Helicobacter pylori in the stomach (UBT value: Δ 13 C (‰)) was calculated from the ratio of the concentration of carbon dioxide containing 13 C in the breath. Thereafter, two capsules of activated carbon powder (prototype) calcined at 1000 ° C. containing high-purity cellulose (including 180 mg of activated carbon powder per tablet) were orally ingested 3 times a day after meals, and expired after ingestion for 3 weeks. The amount of Helicobacter pylori in the stomach (UBT value: Δ 13 C (‰)) was calculated from the ratio of carbon dioxide gas concentration containing 13 C therein. As the breath test apparatus, a carbon dioxide isotope ratio analyzer (manufactured by Otsuka Electronics Co., Ltd., POC one) was used. Exhalation sampling and manipulation were performed according to the manufacturer's instructions. The results are shown in Table 1 below.
Claims (3)
- アンモニア又はアンモニウムイオンの吸着材を含むヘリコバクター・ピロリの除菌剤。 A Helicobacter pylori disinfectant containing ammonia or ammonium ion adsorbent.
- 前記アンモニア又はアンモニウムイオンの吸着材が、活性炭、シリカゲル、アルミナ、ゼオライト、及び陽イオン交換材からなる群から選択される少なくとも1種である請求項1記載の除菌剤。 The disinfectant according to claim 1, wherein the ammonia or ammonium ion adsorbent is at least one selected from the group consisting of activated carbon, silica gel, alumina, zeolite, and cation exchange material.
- ヘリコバクター・ピロリに感染した胃内に請求項1又は2記載の除菌剤を導入するヘリコバクター・ピロリの除菌方法。 A method for sterilizing Helicobacter pylori, which comprises introducing the disinfectant according to claim 1 into the stomach infected with Helicobacter pylori.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800410684A CN102695516A (en) | 2009-09-16 | 2010-09-14 | Eradicating agent and eradication method for helicobacter pylori |
JP2011531926A JPWO2011034039A1 (en) | 2009-09-16 | 2010-09-14 | Helicobacter pylori disinfectant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009214322 | 2009-09-16 | ||
JP2009-214322 | 2009-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011034039A1 true WO2011034039A1 (en) | 2011-03-24 |
Family
ID=43758642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/065787 WO2011034039A1 (en) | 2009-09-16 | 2010-09-14 | Eradicating agent and eradication method for helicobacter pylori |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPWO2011034039A1 (en) |
KR (1) | KR20120051776A (en) |
CN (1) | CN102695516A (en) |
WO (1) | WO2011034039A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020050069A1 (en) * | 2018-09-06 | 2020-03-12 | 日機装株式会社 | Ammonia adsorbent and method for removing ammonia |
JP2020184979A (en) * | 2019-05-17 | 2020-11-19 | 日機装株式会社 | Method for regenerating liquid to be treated |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103316043B (en) * | 2013-06-07 | 2015-10-28 | 逢甲大学 | Containing the medicinal usage of the compositions of carbonaceous material and active particle |
CN103316044B (en) * | 2013-06-07 | 2015-11-04 | 逢甲大学 | For suppressing the compositions structure of intestines and stomach bacteriological infection |
CN110326778A (en) * | 2019-07-13 | 2019-10-15 | 林聪� | Purposes of the diatomite in preparation removal helicobacter pylori food |
CN113274404A (en) * | 2020-06-28 | 2021-08-20 | 天翊生物医药科技(天津)有限公司 | New application of medical adsorption resin and helicobacter pylori eliminating medicine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08337529A (en) * | 1995-06-12 | 1996-12-24 | Motoo Nishimura | Therapeutic agent for disease in superior digestive tract |
JPH0920668A (en) * | 1995-07-07 | 1997-01-21 | Yakurigaku Chuo Kenkyusho:Kk | Antibacterial agent for helicobacter pylori as slightly aerobic gram-negative bacillus |
JPH10109942A (en) * | 1996-08-13 | 1998-04-28 | Takeda Chem Ind Ltd | Medicine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0220668A (en) * | 1988-07-11 | 1990-01-24 | Fanuc Ltd | Torch and plasma arc for plasma arc welding machine |
-
2010
- 2010-09-14 CN CN2010800410684A patent/CN102695516A/en active Pending
- 2010-09-14 KR KR1020127009463A patent/KR20120051776A/en not_active Application Discontinuation
- 2010-09-14 WO PCT/JP2010/065787 patent/WO2011034039A1/en active Application Filing
- 2010-09-14 JP JP2011531926A patent/JPWO2011034039A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08337529A (en) * | 1995-06-12 | 1996-12-24 | Motoo Nishimura | Therapeutic agent for disease in superior digestive tract |
JPH0920668A (en) * | 1995-07-07 | 1997-01-21 | Yakurigaku Chuo Kenkyusho:Kk | Antibacterial agent for helicobacter pylori as slightly aerobic gram-negative bacillus |
JPH10109942A (en) * | 1996-08-13 | 1998-04-28 | Takeda Chem Ind Ltd | Medicine |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020050069A1 (en) * | 2018-09-06 | 2020-03-12 | 日機装株式会社 | Ammonia adsorbent and method for removing ammonia |
JP2020039258A (en) * | 2018-09-06 | 2020-03-19 | 日機装株式会社 | Ammonia adsorbent and method of removing ammonia |
JP7075054B2 (en) | 2018-09-06 | 2022-05-25 | 日機装株式会社 | Ammonia adsorbent and method of removing ammonia |
JP2020184979A (en) * | 2019-05-17 | 2020-11-19 | 日機装株式会社 | Method for regenerating liquid to be treated |
JP7274170B2 (en) | 2019-05-17 | 2023-05-16 | 日機装株式会社 | Method for regenerating liquid to be treated and apparatus for regenerating liquid to be treated |
Also Published As
Publication number | Publication date |
---|---|
JPWO2011034039A1 (en) | 2013-02-14 |
KR20120051776A (en) | 2012-05-22 |
CN102695516A (en) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10864109B2 (en) | Method and system for reducing the likelihood of colorectal cancer in a human being | |
US10086018B2 (en) | Method and system for reducing the likelihood of colorectal cancer in a human being | |
WO2011034039A1 (en) | Eradicating agent and eradication method for helicobacter pylori | |
ES2734979T3 (en) | Composition comprising N-acetylcysteine and probiotic bacteria capable of restoring the stomach barrier effect itself that is lost during gastric hyperacidity treatment with proton pump inhibitors | |
KR101610791B1 (en) | New medical applications of alpha-ketoglutarate | |
EP2712318B1 (en) | Composition comprising probiotic bacteria capable of restoring the barrier effect of the stomach which is lost during pharmalogical treatment of gastric hyperacidity | |
JP3875262B2 (en) | Acidified nitrite as a disinfectant | |
US10638784B2 (en) | Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof | |
WO2019056404A1 (en) | Use of bacteroides fragilis in preparation of medicament for treating and preventing tumor | |
RU2439145C2 (en) | Strain of microorganism bacillus smithii tbm112 mscl p737 and its application as food or feed additive, or component of probiotic composition, and probiotic composition | |
US9357792B2 (en) | Fermented cereal product obtained by fermentation of rye bran with a Lactobacillus curvatus strain | |
Anilkumar et al. | Role of friendly bacteria in oral health-a short review. | |
CN113893353B (en) | Method for improving survival rate of intestinal probiotics in oral delivery process | |
RU2352628C2 (en) | Novel strains of bifidobacteria, possessing ability to pruduce glutamine | |
WO2014057151A1 (en) | Use of the cect 7426 strain for generating quorum quenching of the autoinducer-2 signal (ai-2) | |
CN115666546A (en) | Enteral oxidation therapy | |
RU2501549C1 (en) | Pharmaceutical composition for treating gastroesophageal reflux disease | |
US8758775B2 (en) | Pharmaceutical composition including clinoptilolite | |
TWI718394B (en) | Lactic acid bacteria composition for inhibiting gastritis caused by helicobacter pylori in stomach and its use | |
KR20200107384A (en) | Novel Pediococcus pentosaceus FB145 with removing cadmium and use thereof | |
Goli et al. | Efficacy of probiotics as an adjuvant agent in eradication of Helicobacter pylori infection and associated side effects | |
KR102098029B1 (en) | A composition comprising chitosan for ehancing the the photodynamic therapy against Helicobacter pylori | |
RU2713154C1 (en) | Anti-helicobacter agent and method for use thereof | |
Downey | Probiotic-Phage Blend Fights Digestive Problems and Boosts Immune Defenses. | |
Sukumaran et al. | Can bio-nanotechnology be effective against multi drug resistant (MDR) pathogens? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10817152 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011531926 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127009463 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10817152 Country of ref document: EP Kind code of ref document: A1 |